Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions
CD30 is a member of the tumor necrosis factor receptor superfamily. It is characteristically
expressed in certain hematopoietic malignancies, including anaplastic large cell lymphoma …
expressed in certain hematopoietic malignancies, including anaplastic large cell lymphoma …
Clinical targeting of the TNF and TNFR superfamilies
Inhibitors of tumour necrosis factor (TNF) are among the most successful protein-based
drugs (biologics) and have proven to be clinically efficacious at reducing inflammation …
drugs (biologics) and have proven to be clinically efficacious at reducing inflammation …
Ribosome-inactivating proteins from plants
L Barbieri, MG Battelli, F Stirpe - … et Biophysica Acta (BBA)-Reviews on …, 1993 - Elsevier
The ribosome-inactivating proteins (RIPs) from plants are RNA N-glycosidases that
depurinate the major rRNA, thus damaging ribosomes, and arresting protein synthesis [1-8] …
depurinate the major rRNA, thus damaging ribosomes, and arresting protein synthesis [1-8] …
ALK+ Lymphoma: Clinico-Pathological Findings and Outcome
A distinct pathologic entity (ALK+ lymphoma) that is characterized by expression of the
anaplastic lymphoma kinase (ALK) protein has recently emerged within the heterogeneous …
anaplastic lymphoma kinase (ALK) protein has recently emerged within the heterogeneous …
[HTML][HTML] CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy
SINCE THE INITIAL description of the Ki-1 monoclonal antibody (MoAb) in 1982, 1 there has
been an overwhelming flood of information concerning the Hodgkin's disease (HD) …
been an overwhelming flood of information concerning the Hodgkin's disease (HD) …
Hodgkin's lymphoma: the pathologist's viewpoint
Despite its well known histological and clinical features, Hodgkin's lymphoma (HL) has
recently been the object of intense research activity, leading to a better understanding of its …
recently been the object of intense research activity, leading to a better understanding of its …
A Phase II study of SGN‐30 (anti‐CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma
A Forero‐Torres, JP Leonard, A Younes… - British journal of …, 2009 - Wiley Online Library
Summary SGN‐30, a chimeric anti‐CD30 monoclonal antibody, has demonstrated potent
preclinical antitumour activity in both Hodgkin lymphoma (HL) and anaplastic large cell …
preclinical antitumour activity in both Hodgkin lymphoma (HL) and anaplastic large cell …
Epstein Barr virus–specific cytotoxic T lymphocytes expressing the anti-CD30ζ artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease
Adoptive transfer of Epstein Barr virus (EBV)–specific cytotoxic T-lymphocytes (EBV-CTLs)
has shown that these cells persist in patients with EBV+ Hodgkin lymphoma (HD) to produce …
has shown that these cells persist in patients with EBV+ Hodgkin lymphoma (HD) to produce …
CD30 expression in peripheral T-cell lymphomas
©Ferrata Storti Foundation No commercial use Page 1 CD30 expression in peripheral T-cell
lymphomas CD30 antigen is a trans-membrane glycoprotein belonging to the tumor necrosis …
lymphomas CD30 antigen is a trans-membrane glycoprotein belonging to the tumor necrosis …
Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma
Purpose MDX-060 is a human anti-CD30 immunoglobulin (Ig) G1κ monoclonal antibody that
inhibits growth of CD30-expressing tumor cells in preclinical models. To determine the …
inhibits growth of CD30-expressing tumor cells in preclinical models. To determine the …